Decreased neonatal hepatitis B virus (HBV) viremia by maternal tenofovir treatment predicts reduced chronic HBV infection in children born to highly viremic mothers.
Kai-Chi ChangMei-Hwei ChangChien-Nan LeeChin-Hao ChangJia-Feng WuYen-Hsuan NiWan-Hsin WenMing-Kwang ShyuMing-Wei LaiShih-Ming ChenJen-Jan HuHans Hsienhong LinJenn-Jeih HsuShu-Chi MuYu-Cheng LinChun-Jen LiuDing-Shinn ChenLung-Huang LinHuey-Ling Chennull nullPublished in: Alimentary pharmacology & therapeutics (2019)
Maternal tenofovir therapy decreased maternal viral load and neonatal viremia. Positive neonatal HBV DNA was highly correlated with chronic HBV infection in children. Clinical Trial Identifier: NCT01312012.
Keyphrases
- hepatitis b virus
- birth weight
- liver failure
- clinical trial
- pregnancy outcomes
- young adults
- gestational age
- antiretroviral therapy
- randomized controlled trial
- circulating tumor
- physical activity
- mesenchymal stem cells
- drug induced
- combination therapy
- body mass index
- preterm birth
- cell therapy
- bone marrow
- smoking cessation